Outcomes of renal transplantation in recipients with peak panel reactive antibody >30% under tacrolimusbased immunosuppression

Annals of Transplantation

Volumn 16, Issue 3, 2011, Pages 5-13

  Basu, Amit ^a   Falcone, John ^b   Dvorchik, Igor ^a   Tan, Henkie P ^a   Schonder, Kristine ^c   Wallis Marsh, J ^a   Zeevi, Adriana ^a   Humar, Abhinav ^a   Shapiro, Ron ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Calcineurin inhibitors; Clinical outcomes; Cross matching; HLA typing; Presensitization

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; OKT 3; PANEL REACTIVE ANTIBODY; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CADAVER KIDNEY; CYTOTOXICITY TEST; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; SENSITIZATION; SURVIVAL; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 80054861549     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.881988     Document Type: Article

References (19)

1. Crew RJ, Ratner LE: Overcoming Immunologic Incompatibility: Transplanting the difficult to transplant patient. Semin Dial, 2005; 18(6): 474-81
2. Lieber SR, Perez FVT, Tabossi MR et al: Effect of panel-reactive antibody in predicting crossmatch selection of cadaveric kidney recipients. Transplant Proc, 2007; 39: 429-31
3. Katznelson S, Bhaduri S, Cecka JM: Clinical aspects of sensitization. In: Cecka JM, Terasaki PI (eds.), Clinical Transplants 1997. Los Angeles, CA. UCLA Tissue Typing Laboratory, 1998: 285-96
4. Barama A, Oza U, Panek R et al: Effect of recipient sensitization (peak PRA) on graft outcome in haploidentical living related kidney transplants. Clin Transplantation, 2000; 14(3): 212-17
5. Hardy S, Lee SH, Terasaki PI: Sensitization 2001. In: Cecka JM, Terasaki PI (eds.), Clinical Transplants 2001. Los Angeles, CA. UCLA Tissue Typing Laboratory, 2001; 271-78
6. Bartel G, Wahrmann M, Exner M et al: Determinants of the complement-fixing ability of recipient presensitization against HLA antigens. Transplantation, 2007; 83(6): 727-33
7. Wahrmann M, Exner M, Schillinger M et al: Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Am J Transplant, 2006; 6: 1033-41
8. Nogueria JM, Schweitzer EJ: Aapproach to the Highly Sensitized Patient. In Weir M R, Ed. Medical Management of Kidney Transplantation. Philadelphia, PA. Lippincott, Williams and Wilkins, 2005: 53-64
9. Ogura K: Sensitization. In: Cecka JM, Terasaki PI (eds.), Clinical Transplants, 1992. Los Angeles, CA. UCLA Tissue Typing Laboratory, 1992; 357-69
10. 2007 OPTN/SRTR Annual Report. Available at: http://www.optn.org/ar2007 Accessed May 20, 2009
11. Koyama H, Cecka JM: Rejection episodes. In: Cecka JM, Tersaki PI (eds.), Clinical Transplants 1992. Los Angeles, CA. UCLA Tissue Typing Laboratory, 1992: 391-404
12. Humar A, Hassoun A, Kandaswamy R et al: Immunologic risk factors: The major risk for decreased long-term renal allograft survival. Transplantation, 1999; 68(12): 1842-46
13. van de Watering L, Hermans J, Witvliet M et al: HLA and RBC immunization after filtered and buffy coat-depleted blood transfusion in cardiac surgery: a randomized controlled trial. Transfusion, 2003; 43: 765-71
14. Gottvall T, Filbey D: Alloimmunization in pregnancy during the years 1992-2005 in the central west region of Sweden. Acta Obstet Gynecol Scand, 2008; 87: 843-48
15. Singh D, Kiberd A, West K A et al: Importance of peak PRA in predicting the kidney transplant survival in Highly Sensitized Patients. Transplant Proc, 2003; 35: 2395-97
16. Fuggle S V, Martin S: Tools for Human Leukocyte Antigen Antibody Detection and Their Application to Transplanting Sensitized Patients. Transplantation, 2008; 86: 384-90
17. Cecka JM: Calculated PRA (CPRA): The New Measure of Sensitization for Transplant Candidates. Am J Transplant, 2010; 10: 26-29
18. Szczech LA, Berlin JA, Feldman HI: The effect of antilymphocyte induction therapy on renal allograft survival: A meta-analysis of individual patientlevel data. Ann Internal Med, 1998; 128: 817-26
19. Thibaudin D, Alamartine E, de Filippis J-P et al: Advantages of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant, 1998; 13(3): 711-15